GSK114: A selective inhibitor for elucidating the biological role of TNNI3K
Authors:
- 1 July 2016
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (14) , 3355-3358
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K)Journal of Medicinal Chemistry, 2015
- Troponin I-Interacting Protein KinaseCirculation Journal, 2014
- Inhibition of the Cardiomyocyte-Specific Kinase TNNI3K Limits Oxidative Stress, Injury, and Adverse Remodeling in the Ischemic HeartScience Translational Medicine, 2013
- Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunctionJournal of Molecular and Cellular Cardiology, 2013
- Adenovirus‐mediated overexpression of cardiac troponin I‐interacting kinase promotes cardiomyocyte hypertrophyClinical and Experimental Pharmacology and Physiology, 2011
- Tnni3k Modifies Disease Progression in Murine Models of CardiomyopathyPLOS Genetics, 2009
- Role of Raf Proteins in Cardiac Hypertrophy and Cardiomyocyte SurvivalTrends in Cardiovascular Medicine, 2005
- Raf-1 Kinase Is Required for Cardiac Hypertrophy and Cardiomyocyte Survival in Response to Pressure OverloadCirculation, 2004